See more : Packaging Corporation of America (PKG) Income Statement Analysis – Financial Results
Complete financial analysis of AVITA Medical, Inc. (RCEL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of AVITA Medical, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Absci Corporation (ABSI) Income Statement Analysis – Financial Results
- Kyobo 16 SPAC (482520.KQ) Income Statement Analysis – Financial Results
- TeraGo Inc. (TGO.TO) Income Statement Analysis – Financial Results
- Pulstec Industrial Co., Ltd. (6894.T) Income Statement Analysis – Financial Results
- Beijing-Shanghai High-Speed Railway Co.,Ltd. (601816.SS) Income Statement Analysis – Financial Results
AVITA Medical, Inc. (RCEL)
About AVITA Medical, Inc.
AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients eighteen years and older. The company has a research collaboration with the University of Colorado School of Medicine to establish pre-clinical proof-of-concept for a spray-on treatment of genetically corrected cells; and a research collaboration with Houston Methodist Research Institute to explore molecular reversal of cellular aging through a novel cell suspension delivery system. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical Inc. in December 2020. AVITA Medical Inc. was incorporated in 2000 and is based in Valencia, California.
| Metric | 2022 | 2020 | 2019 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 50.56M | 14.26M | 20.67M | 1.26M | 1.18M | 1.00M | 985.65K | 2.68M | 2.81M | 3.35M | 3.34M | 2.30M | 2.37M | 1.20M | 790.99K | 883.39K | 389.08K | 194.32K | 0.00 | 0.00 | 0.00 | 582.97K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 8.87M | 2.97M | 4.31M | 737.70K | 505.64K | 401.57K | 289.20K | 670.89K | 676.50K | 952.85K | 972.78K | 669.45K | 824.23K | 492.31K | 1.13M | 1.06M | 940.26K | 98.98K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 41.69M | 11.29M | 16.36M | 517.47K | 675.00K | 600.44K | 696.45K | 2.01M | 2.14M | 2.40M | 2.36M | 1.63M | 1.54M | 711.35K | -337.70K | -176.85K | -551.18K | 95.34K | 0.00 | 0.00 | 0.00 | 582.97K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 82.45% | 79.16% | 79.16% | 41.23% | 57.17% | 59.92% | 70.66% | 75.00% | 75.97% | 71.58% | 70.84% | 70.85% | 65.18% | 59.10% | -42.69% | -20.02% | -141.66% | 49.06% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 20.35M | 8.46M | 13.28M | 8.45M | 6.27M | 3.46M | 3.77M | 2.15M | 2.60M | 969.11K | 255.54K | 164.79K | 181.85K | 163.83K | 620.67K | 1.33M | 425.97K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 34.27M | 34.62M | 46.77M | 12.70M | 0.00 | 6.51M | 2.45M | 4.27M | 5.45M | 5.34M | 5.42M | 3.40M | 3.87M | 3.98M | 5.36M | 5.64M | 2.21M | 725.90K | 480.40K | 569.49K | 235.70K | 371.78K | 97.16K | 138.81K | 126.55K | 278.48K | 207.93K |
| Selling & Marketing | 32.19M | 14.81M | 22.76M | 6.59M | 5.20M | 3.46M | 3.21M | 2.63M | 3.39M | 2.93M | 2.15M | 1.15M | 1.37M | 1.39M | 1.92M | 1.90M | 838.56K | 122.35K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 66.46M | 49.43M | 70.61M | 21.21M | 13.90M | 10.93M | 5.68M | 7.09M | 8.92M | 8.44M | 7.57M | 4.55M | 5.24M | 5.37M | 7.28M | 7.54M | 3.05M | 848.25K | 480.40K | 569.49K | 235.70K | 371.78K | 97.16K | 138.81K | 126.55K | 278.48K | 207.93K |
| Other Expenses | 0.00 | 686.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 852.27K | 886.45K | 41.73K | 5.88K | 4.27M | 85.29K | 240.35K | -1.28M | -24.61K | -2.08M | 28.27K | -956.00K | -1.56M | 1.52M | 910.39K | 40.34K | 16.93K |
| Operating Expenses | 80.78M | 53.97M | 77.21M | 19.15M | 13.35M | 11.95M | 9.26M | 8.83M | 10.77M | 10.66M | 7.89M | 5.23M | 5.91M | 5.75M | 8.75M | 9.62M | 4.87M | 169.38K | 670.01K | 76.87K | 235.70K | 371.78K | 97.16K | 138.81K | 126.55K | 278.48K | 207.93K |
| Cost & Expenses | 89.65M | 56.94M | 81.51M | 19.88M | 13.85M | 12.36M | 9.55M | 9.50M | 11.45M | 11.61M | 8.86M | 5.90M | 6.74M | 6.25M | 9.88M | 10.68M | 5.81M | 268.36K | 670.01K | 76.87K | 235.70K | 371.78K | 97.16K | 138.81K | 126.55K | 278.48K | 207.93K |
| Interest Income | 23.50K | 0.00 | 47.82K | 28.37K | 110.96K | 110.34K | 45.42K | 160.33K | 412.26K | 497.99K | 124.99K | 124.70K | 270.11K | 668.21K | 543.41K | 520.50K | 201.65K | 145.15K | 126.13K | 195.94K | 6.81K | 609.80 | 4.20K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 33.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12.90K | 37.65K | 78.50K | 53.20K | 8.55M | 4.86K | 9.95K | 2.26K | 3.57 | 4.97M | 576.36K | 2.07M | 2.19M | 258.33K | 1.16M | 775.70 | -191.00K |
| Depreciation & Amortization | 1.46M | 465.00K | 0.00 | 105.45K | 139.70K | 83.72K | 62.62K | 63.71K | 121.92K | 569.23K | 650.88K | 517.57K | 491.49K | 221.96K | 852.62K | 745.94K | 702.81K | 111.83K | 189.60K | 76.87K | 595.35K | -923.38K | -2.19M | 578.99K | -1.16M | -1.96M | 49.44K |
| EBITDA | -39.57M | -41.53M | -61.17M | -18.55M | -12.53M | -11.27M | -8.68M | -6.76M | -8.51M | -5.62M | -3.89M | -2.08M | -3.57M | -4.15M | -3.69M | -8.45M | -4.27M | -1.39M | -390.45K | 575.84K | 359.65K | 582.97K | -2.29M | 440.17K | -1.29M | -2.23M | -158.49K |
| EBITDA Ratio | -78.26% | -291.16% | -295.97% | -1,478.04% | -1,061.34% | -1,124.79% | -880.69% | -251.79% | -302.36% | -167.75% | -116.76% | -90.46% | -150.78% | -344.42% | -466.58% | -956.13% | -1,097.89% | -717.25% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -40.40M | -42.68M | -61.84M | -18.70M | -12.67M | -11.35M | -8.74M | -6.82M | -8.63M | -6.19M | -4.38M | -2.59M | -4.06M | -4.37M | -4.54M | -9.19M | -4.97M | -1.62M | -1.29M | 498.37K | -235.70K | 1.51M | -97.16K | -138.81K | -126.55K | -278.48K | -207.93K |
| Operating Income Ratio | -79.91% | -299.23% | -299.23% | -1,489.88% | -1,073.17% | -1,133.14% | -887.04% | -254.16% | -306.69% | -184.73% | -131.31% | -113.00% | -171.55% | -362.86% | -574.37% | -1,040.57% | -1,278.53% | -832.34% | 0.00% | 0.00% | 0.00% | 258.39% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.29M | 686.00K | 946.20K | 43.24K | 110.96K | 110.34K | 222.97K | 160.33K | 412.26K | -1.57M | 3.23M | -1.82M | 41.73K | -7.58M | -4.55M | 85.29K | 240.35K | -1.58M | -735.53K | -1.16M | -567.08K | -956.00K | -1.56M | 1.52M | 911.13K | 99.29K | 158.49K |
| Income Before Tax | -39.12M | -42.03M | -60.90M | -18.66M | -12.56M | -11.24M | -8.52M | -6.66M | -8.22M | -7.76M | -2.18M | -5.34M | -4.14M | -12.00M | -13.09M | -9.20M | -4.98M | -1.51M | -1.29M | -1.63M | -812.06K | -563.08K | -2.29M | 184.42K | -1.29M | -2.18M | -16.93K |
| Income Before Tax Ratio | -77.36% | -294.65% | -294.65% | -1,486.44% | -1,063.77% | -1,122.13% | -864.42% | -248.18% | -292.04% | -231.47% | -65.24% | -232.33% | -174.86% | -997.23% | -1,655.44% | -1,041.12% | -1,281.08% | -775.96% | 0.00% | 0.00% | 0.00% | -96.59% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 52.88K | 4.00K | 5.80K | 1.45M | 1.05M | 971.88K | 653.67K | 1.51M | 128.05K | 87.76K | -90.09K | -330.41K | 78.50K | -342.23K | -316.55K | -311.92K | -7.13M | -2.69M | -2.53M | -2.94M | 576.36K | -923.38K | 2.19M | -581.57K | 1.16M | -238.92K | 208.61K |
| Net Income | -39.17M | -42.03M | -60.90M | -17.21M | -11.51M | -10.27M | -7.87M | -5.15M | -8.09M | -7.59M | -2.09M | -5.01M | -4.14M | -11.66M | -12.78M | -8.89M | -4.98M | -1.54M | -1.12M | -1.54M | -812.06K | -562.85K | -2.29M | 184.42K | -1.29M | -1.94M | -225.54K |
| Net Income Ratio | -77.47% | -294.68% | -294.68% | -1,370.83% | -974.99% | -1,025.14% | -798.10% | -191.84% | -287.49% | -226.42% | -62.54% | -217.95% | -174.86% | -968.80% | -1,615.42% | -1,005.81% | -1,281.08% | -794.76% | 0.00% | 0.00% | 0.00% | -96.55% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.57 | -2.07 | -3.00 | -1.84 | -1.72 | -2.06 | -2.23 | -1.58 | -2.69 | -3.19 | -1.53 | -3.93 | -3.75 | -16.51 | -3.24 | -3.43 | -3.14 | -1.92 | -0.56 | -0.80 | -1.32 | -2.25 | -48.58 | -0.74 | -27.28 | -42.11 | -5.06 |
| EPS Diluted | -1.57 | -2.07 | -3.00 | -1.85 | -1.72 | -2.06 | -2.23 | -1.58 | -2.69 | -3.19 | -1.53 | -3.93 | -3.75 | -16.51 | -3.24 | -3.43 | -3.14 | -1.92 | -0.56 | -0.80 | -1.32 | -2.25 | -48.58 | -0.74 | -27.28 | -42.11 | -5.06 |
| Weighted Avg Shares Out | 25.00M | 20.29M | 20.29M | 9.30M | 6.69M | 4.99M | 3.53M | 3.25M | 3.01M | 2.38M | 1.36M | 1.27M | 1.10M | 706.45K | 3.94M | 2.59M | 1.59M | 806.03K | 2.00M | 1.93M | 614.53K | 249.70K | 47.13K | 47.13K | 47.13K | 46.02K | 44.55K |
| Weighted Avg Shares Out (Dil) | 25.00M | 20.29M | 20.29M | 9.33M | 6.70M | 4.99M | 3.53M | 3.25M | 3.01M | 2.38M | 1.36M | 1.27M | 1.10M | 706.45K | 3.94M | 2.59M | 1.59M | 806.03K | 2.00M | 1.93M | 614.53K | 249.70K | 47.13K | 47.13K | 47.13K | 46.02K | 44.55K |
AVITA Medical Positioned For Stellar 2024 With Skin Repair Innovation Momentum
AVITA Medical's Spray-On Skin Cells device rapidly processes a patient's own skin to treat large dermatological injuries. The company's sales growth is expected to accelerate in 2024 due to the supplement of its RECELL System for full-thickness skin defects. AVITA's...
AVITA Medical to Host Investor Webinar Briefing
VALENCIA, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, invites shareholders and prospective...
Avita (RCEL) Falls 19% on Lowered 2023 Revenue Guidance
Avita's (RCEL) stock declines 19% after the company lowered its total revenue guidance for 2023.
AVITA Medical to Present at the Piper Sandler 35th Annual Healthcare Conference
VALENCIA, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced that Jim...
AVITA Medical Updates Full Year 2023 Guidance
VALENCIA, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced an update...
AVITA Medical, Inc. (RCEL) Q3 2023 Earnings Call Transcript
AVITA Medical, Inc. (NASDAQ:RCEL ) Q3 2023 Results Conference Call November 9, 2023 4:30 PM ET Company Participants Jessica Ekeberg - Director of Investor Relations Jim Corbett - Chief Executive Officer David O'Toole - Chief Financial Officer Conference Call Participants...
AVITA Medical Reports Third Quarter Financial Results with 51% Revenue Growth over the Same Period the Prior Year
VALENCIA, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today reported financial results...
AVITA Medical Announces Distribution Partnership with PolyMedics Innovations to Expand to Europe
AVITA Medical announced it has entered into a distribution agreement with PolyMedics Innovations, to strategically expand its global presence to Europe.
AVITA Medical to Announce Third Quarter 2023 Financial Results
VALENCIA, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced that it will report...
Why Shares of Avita Medical Are Down Monday
The FDA is asking for more information regarding Avita's Recell Go device. The Recell Go is a more automated version of an already approved product for Avita.
Source: https://incomestatements.info
Category: Stock Reports